Prevention of Accelerated Atherosclerosis by Angiotensin-Converting Enzyme Inhibition in Diabetic Apolipoprotein E–Deficient Mice
Open Access
- 9 July 2002
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 106 (2), 246-253
- https://doi.org/10.1161/01.cir.0000021122.63813.32
Abstract
Background — Atherosclerosis is a major complication of diabetes, but the mechanisms by which diabetes promotes macrovascular disease have not been fully delineated. Although several animal studies have demonstrated that inhibition of ACE results in a decrease in the development of atherosclerotic lesions, information about the potential benefits of these agents on complex and advanced atherosclerotic lesions as observed in long-term diabetes is lacking. The aim of this study was to evaluate whether treatment with the ACE inhibitor perindopril affects diabetes-induced plaque formation in the apolipoprotein E (apoE)-deficient mouse. Methods and Results — Diabetes was induced by injection of streptozotocin in 6-week-old apoE-deficient mice. Diabetic animals received treatment with perindopril (4 mg · kg −1 · d −1 ) or no treatment for 20 weeks. Nondiabetic apoE-deficient mice were used as controls. Induction of diabetes was associated with a 4-fold increase in plaque area compared with nondiabetic animals. This accelerated atherosclerosis was associated with a significant increase in aortic ACE expression and activity and connective tissue growth factor and vascular cell adhesion molecule-1 expression. Perindopril treatment inhibited the development of atherosclerotic lesions and diabetes-induced ACE, connective tissue growth factor, and vascular cell adhesion molecule-1 overexpression in the aorta. Conclusions — The activation of the local renin-angiotensin system in the diabetic aorta and the reduction in atherosclerosis with ACE inhibitor treatment provides further evidence that the renin-angiotensin system plays a pivotal role in the development and acceleration of atherosclerosis in diabetes.Keywords
This publication has 20 references indexed in Scilit:
- The Low Density Lipoprotein Receptor-related Protein/α2-Macroglobulin Receptor Is a Receptor for Connective Tissue Growth FactorPublished by Elsevier BV ,2001
- Accelerated atherosclerosis and premature calcified cartilaginous metaplasia in the aorta of diabetic male Apo E knockout mice can be prevented by chronic treatment with 17β-estradiolAtherosclerosis, 1999
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproductsNature Medicine, 1998
- Pathogenesis, prevention, and treatment of diabetic nephropathyThe Lancet, 1998
- Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products.JCI Insight, 1997
- Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnoverThe American Journal of Cardiology, 1995
- Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage—foam cell accumulation independently of blood pressure and plasma lipidsAtherosclerosis, 1994
- Expression of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein and scavenger receptor in human atherosclerotic lesions.JCI Insight, 1994
- LOCALIZATION OF ANGIOTENSIN CONVERTING ENZYME IN RAT FOREBRAIN AND OTHER TISSUES BY IN VITRO AUTORADIOGRAPHY USING 125‐I‐LABELLED MK351AClinical and Experimental Pharmacology and Physiology, 1984